Valuation: Vivos Therapeutics, Inc.

Market Cap 24.52L 22L 20.34L 18.42L 34.42L 23Cr 34.84L 2.43Cr 96.88L 12Cr 92.03L 90.09L 39Cr P/E 2026 *
-0.09x
P/E 2027 * -0.15x
Enterprise Value 24.52L 22L 20.34L 18.42L 34.42L 23Cr 34.84L 2.43Cr 96.88L 12Cr 92.03L 90.09L 39Cr EV / Sales 2026 *
0.11x
EV / Sales 2027 * 0.07x
Free-Float
88.68%
Yield 2026 *
-
Yield 2027 * -
1 day-4.99%
1 week-9.50%
Current month-17.58%
1 month-9.10%
3 months-70.98%
6 months-85.65%
Current year-94.00%
1 week 0.12
Extreme 0.1183
0.13
1 month 0.12
Extreme 0.1183
0.16
Current year 0.12
Extreme 0.1183
2.69
1 year 0.12
Extreme 0.1183
2.72
3 years 0.12
Extreme 0.1183
48.79
5 years 0.12
Extreme 0.1183
106.75
10 years 0.12
Extreme 0.1183
360.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 01/09/2016
Chief Executive Officer 68 01/09/2016
Director TitleAgeSince
Chairman 68 01/06/2020
Director/Board Member 87 01/06/2020
Director/Board Member 59 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Other

Director

12,000 0.0596%
14/09/26 Free

Director

12,000 0.0596%
31/07/26 Free

Chief Financial Officer

4,00,000 2.8788%
Change 5-day change 1-year change 3-year change Capi.($)
-4.99%-9.50%-95.31%-97.18% 24.52L
-0.45%+2.12%-18.93%+10.54% 18TCr
+0.86%+2.15%-19.13%+16.07% 12TCr
+0.88%+1.88%+1.66%+36.51% 12TCr
-2.26%+2.24%-44.03%+5.76% 9.1TCr
-0.31%-4.72%-3.36%+72.86% 6.19TCr
-0.32%-0.19%+10.38%+83.80% 5.58TCr
+0.07%+0.42%+5.94%-22.43% 5.32TCr
+0.30%+1.70%-11.26%+43.83% 4.43TCr
+0.10%+3.08%-3.06%-8.71% 3.36TCr
Average -0.61%-0.10%-17.71%+14.11% 7.5TCr
Weighted average by Cap. -0.13%+1.25%-12.43%+24.20%

Financials

2026 *2027 *
Net sales 2.18Cr 1.95Cr 1.81Cr 1.64Cr 3.06Cr 207.52Cr 3.1Cr 22Cr 8.61Cr 108.59Cr 8.18Cr 8Cr 344.74Cr 3.41Cr 3.06Cr 2.83Cr 2.56Cr 4.78Cr 324.65Cr 4.84Cr 34Cr 13Cr 169.88Cr 13Cr 13Cr 539.32Cr
Net income -2.38Cr -2.14Cr -1.98Cr -1.79Cr -3.35Cr -227.06Cr -3.39Cr -24Cr -9.42Cr -118.82Cr -8.95Cr -8.76Cr -377.2Cr -1.47Cr -1.32Cr -1.22Cr -1.1Cr -2.06Cr -140.04Cr -2.09Cr -15Cr -5.81Cr -73Cr -5.52Cr -5.4Cr -232.64Cr
Net Debt - -
Projected Income Statement - Annual - Vivos Therapeutics, Inc.
Logo Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.
Employees
268
Date Price Change Volume
28/26/28 $0.1219 -4.99% 8,28,813
27/26/27 $0.1283 -2.28% 9,23,787
26/26/26 $0.1313 -1.80% 6,66,336
23/26/23 $0.1337 +0.91% 9,36,317
22/26/22 $0.1325 -1.63% 19,27,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Vivos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.1219USD
Average target price
1.925USD
Spread / Average Target
+1,479.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vivos Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VVOS Stock